CA-XSOLLA
17.7.2024 14:01:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of Xsolla Instant Game Sales, Instant Launcher, and Instant Cloud Gaming following the release of Instant Web Shop in March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717305685/en/
(Graphic: Xsolla)
We have listened to developers express their primary challenges—resource allocation is crucial, yet many struggle to quickly go live with their games and offerings. In response, our streamlined approach facilitates seamless integration and provides developers of any size with instant tools to open new revenue streams for their games. Xsolla partners with game developers and studios of all sizes, offering a swift process to sign license agreements, integrate solutions, and generate revenue promptly, accelerating go-to-market time with direct-to-consumer solutions.
David Stelzer, President of Xsolla, comments: "Xsolla Instant Solutions suite enables developers to quickly and easily launch new monetization channels for their games, attract new paying audiences, and boost revenue by leveraging Xsolla’s comprehensive suite of solutions. We aim to help developers unlock new revenue opportunities while reducing time to market to one day, similar to what we did with the Instant Web Shop launch earlier this year."
Instant Web Shop
Instant Web Shop enables game developers to swiftly set up a fully operational online store for their mobile games, seamlessly transforming a simple link into a revenue-generating platform. This solution increases awareness of the advantages of online purchases and facilitates an effortless shift to a robust LiveOps monetization system, enhancing user engagement and maximizing revenue streams. Instant Web Shop also helps game developers generate more value and purchases with personalization, limited-time offers, promotions, and deep linking.
For more information about Xsolla Instant Web Shop or to sign up, visit: xsolla.pro/ws1
Instant Game Sales
Instant Game Sales empowers developers to create store pages and initiate direct-to-consumer sales by importing content directly from Steam and Epic Game Store. This enables developers to integrate these offerings into their Game Sales page. It facilitates immediate game key sales during pre-orders and pre-launch phases, game releases, and seasonal promotions.
For more information about Xsolla Instant Game Sales or to sign up, visit: xsolla.pro/gs1
Instant Launcher
The Instant Launcher is receiving a significant update to enhance its content delivery system. Developers can import content directly from Steam and Epic Game Store to access a pre-designed launcher app with pre-created design, details, and assets to enable instant direct-to-consumer distribution of their games. Instant Launcher benefits games at any release stage, powering test flights during pre-launch, upcoming launch, and further game monetization. With Launcher, developers can easily directly engage with their audience while cross-promoting their games inside one gaming hub, decreasing the average cost per lead.
For more information about Xsolla Instant Launcher or to sign up, visit: xsolla.pro/launcher1
Instant Xsolla Cloud Gaming
Instant Cloud Gaming offers a self-serve solution for seamless game distribution by rapidly launching a branded cloud gaming platform in as little as 30 minutes to 24 hours. Xsolla Cloud Gaming enables developers to engage directly with their audience by offering pre-launch testing, sharing early versions of their games with the community, and providing the opportunity to demo the game directly from the landing page. Scaling game access to any device ensures quick access to new revenue streams and guarantees reaching more players globally.
For more information about Xsolla Instant Cloud Gaming or to sign up, visit: xsolla.pro/cg1
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717305685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom